Literature DB >> 32056724

Primary cardiac hospitalizations in pulmonary arterial hypertension: Trends and outcomes from 2001 to 2014.

Eileen M Harder1, Aeron M Small2, Wassim H Fares3.   

Abstract

BACKGROUND: Hospitalizations in pulmonary arterial hypertension (PAH) are common and are often for cardiac conditions. Using the National (Nationwide) Inpatient Sample (NIS), we examined characteristics and mortality of primary cardiac hospitalizations in PAH from 2001 to 2014.
METHODS: Adult hospitalizations with any diagnosis code for PAH were identified. Primary cardiac disease was defined as a primary discharge diagnosis of congestive heart failure (CHF), pulmonary heart disease, coronary atherosclerosis, acute myocardial infarction, dysrhythmia, conduction disorder, cardiomyopathy or carditis, heart valve disorder, or cardiac arrest. Temporal trends, characteristics, and in-hospital mortality were analyzed.
RESULTS: From 2001 to 2014, there were 207,095 hospitalizations in PAH, of which 100,509 (48.5%) carried a primary cardiac diagnosis. Most primary cardiac hospitalizations in PAH were for CHF, and pneumonia was the most common primary non-cardiac diagnosis. Over the study period, primary cardiac hospitalizations in PAH fell from 52.9% to 41.4% (p < 0.001). CHF was the most frequent primary cardiac diagnosis associated with death, with sepsis representing the most common primary non-cardiac disease (1,226; 25.0%). Overall, the mortality in primary cardiac hospitalizations in PAH was 5.3% (vs. in primary non-cardiac, 6.9%, p < 0.001). On multivariable analysis, a primary cardiac discharge diagnosis remained associated with a decreased risk of death (odds ratio 0.85, p = 0.010).
CONCLUSION: Primary cardiac hospitalizations in PAH are common and are associated with decreased mortality compared to admissions for primary non-cardiac diagnoses.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cardiac hospitalizations; Outcomes; Pulmonary arterial hypertension

Year:  2019        PMID: 32056724     DOI: 10.1016/j.rmed.2019.105850

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  3 in total

1.  COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City.

Authors:  Roxana Sulica; Frank Cefali; Caroline Motschwiller; Rebecca Fenton; Anabela Barroso; Daniel Sterman
Journal:  Diagnostics (Basel)       Date:  2021-01-15

2.  The impact of COVID-19 pandemic on pulmonary hypertension: What have we learned?

Authors:  Williams Hinojosa; María José Cristo-Ropero; Alejandro Cruz-Utrilla; Teresa Segura de la Cal; Francisco López-Medrano; Rafael Salguero-Bodes; Carmen Pérez-Olivares; Begoña Navarro; Nuria Ochoa; Fernando Arribas Ynsurriaga; Pilar Escribano-Subias
Journal:  Pulm Circ       Date:  2022-10-01       Impact factor: 2.886

3.  Hospital outcomes for patients with pulmonary arterial hypertension in sepsis and septic shock.

Authors:  Rhythm Vasudeva; Abhiram Challa; Nicholas Tuck; Suveeenkrishna Pothuru; Mohinder Vindhyal
Journal:  BMC Pulm Med       Date:  2022-10-03       Impact factor: 3.320

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.